$ cat ./records/gates-foundation-commits-50-million-to-vir-biotechnology-for-hiv--2022.txt
Gates Foundation Commits $50 Million to Vir Biotechnology for HIV Broadly Neutralising Antibody Functional Cure
[RECORD.TXT] · cat --full
In January 2022, the Gates Foundation committed $50 million to Vir Biotechnology — a $40 million equity stake through its Strategic Investment Fund and a $10 million grant — to advance broadly neutralising antibodies engineered to suppress HIV replication and provide a 'vaccinal effect.' The programme includes a clinical proof-of-concept trial in HIV-infected adults and preclinical malaria prevention research. Vir had previously developed the COVID-19 treatment sotrovimab with GSK; the new programme applies the same antibody engineering platform to HIV.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
IAVI HIV Vaccine Trials Backed by Gates Foundation CAVD Show First Proof-of-Concept for Broadly Neutralising Antibody Priming
Next →
Gates Foundation Pledges $912 Million to Global Fund — Largest-Ever Commitment to Fight HIV, TB, and Malaria by 2030
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.